{"DataElement":{"publicId":"6788127","version":"1","preferredName":"Minimal Residual Disease Next Generation Flow Diagnostic Sensitivity Specify Text","preferredDefinition":"The free-text field that describes the minimal residual disease next generation flow diagnostics sensitivity.","longName":"6788124v1.0:2799057v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6788124","version":"1","preferredName":"Minimal Residual Disease Next Generation Flow Diagnostic Sensitivity","preferredDefinition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques._A highly-sensitive variant of flow cytometry used to monitor minimal residual disease (MRD). It makes use of an optimized combination of fluorochromes and antibody reagents for increased specificity at very low MRD levels._The probability that a test will produce a true postive result when used on effected subjects as compared to a reference or \"gold standard\". The sensitivity of a test can be determined by calculating: number of true positive results divided by the sum of true positive results plus number of false negative results.","longName":"6788122v1.0:6783021v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6788122","version":"1","preferredName":"Minimal Residual Disease Next Generation Flow","preferredDefinition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.:A highly-sensitive variant of flow cytometry used to monitor minimal residual disease (MRD). It makes use of an optimized combination of fluorochromes and antibody reagents for increased specificity at very low MRD levels.","longName":"C3896:C161822","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Next Generation Flow","conceptCode":"C161822","definition":"A highly-sensitive variant of flow cytometry used to monitor minimal residual disease (MRD). It makes use of an optimized combination of fluorochromes and antibody reagents for increased specificity at very low MRD levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC255B5-7200-441C-E053-F662850A19B2","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"ONEDATA","dateModified":"2019-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6783021","version":"1","preferredName":"Diagnostic Sensitivity","preferredDefinition":"The probability that a test will produce a true postive result when used on effected subjects as compared to a reference or \"gold standard\". The sensitivity of a test can be determined by calculating: number of true positive results divided by the sum of true positive results plus number of false negative results.","longName":"C41394","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnostic Sensitivity","conceptCode":"C41394","definition":"The probability that a test will produce a true postive result when used on effected subjects as compared to a reference or \"gold standard\". The sensitivity of a test can be determined by calculating: number of true positive results divided by the sum of true positive results plus number of false negative results.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B8A555D-83AE-130A-E053-F662850AC9BB","latestVersionIndicator":"Yes","beginDate":"2019-06-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-17","modifiedBy":"ONEDATA","dateModified":"2019-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC255B5-720E-441C-E053-F662850A19B2","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2799057","version":"1","preferredName":"Specify Text","preferredDefinition":"Be specific about something; define clearly._Text; the words of something written.","longName":"SPC_TXT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2799056","version":"1","preferredName":"Specify Text","preferredDefinition":"Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D89B-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"ONEDATA","dateModified":"2008-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D8AC-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"MALUMK","dateModified":"2021-01-19","changeDescription":"03/17/10-Added CSI for F2000-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify the minimal residual","type":"Preferred Question Text","description":"Specify the minimal residual disease next generation flow diagnostics sensitivity:","url":null,"context":"NHLBI"},{"name":"Specify other sensitivity:","type":"Alternate Question Text","description":"Specify other sensitivity:","url":null,"context":"NHLBI"},{"name":"Specify other sensitivity:","type":"Application Standard Question Text","description":"Specify other sensitivity:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BC299B9-A461-7920-E053-F662850A3F92","latestVersionIndicator":"Yes","beginDate":"2019-06-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-20","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":". System generated def displayed as alt def.; . System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}